Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis

被引:42
作者
Yamashita, H. [1 ]
Iwase, H. [2 ]
Toyama, T.
Takahashi, S. [3 ]
Sugiura, H.
Yoshimoto, N.
Endo, Y.
Fujii, Y.
Kobayashi, S.
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan
[2] Kumamoto Univ, Dept Breast & Endocrine Surg, Kumamoto, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Aichi 4678601, Japan
关键词
breast cancer; estrogen receptor; HER2; incidence; Japanese; prognosis; GENOME-WIDE ASSOCIATION; RISK-FACTORS; TAMOXIFEN; EXPRESSION; SUSCEPTIBILITY; ANASTROZOLE; COMBINATION; RECURRENCE; LETROZOLE; SUBTYPES;
D O I
10.1093/annonc/mdq596
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The incidence of breast cancer in Japanese women has doubled in all age groups over the past two decades. Patients and methods: We examined the characteristics of the tumors treated in three time periods between 1982 and 2010. Estrogen receptor (ER), progesterone receptor (PgR) and HER2 status were assessed by immunohistochemistry. Correlation of hormone receptor levels with clinicopathological factors and prognosis was analyzed in ER-positive, HER2-negative breast cancer in two age groups (<= 50 years versus >50 years). Results: The frequency of ER-positive breast cancer in women aged 50 years or younger increased greatly over the interval studied (1982-1991: 52.5%, 1992-2001: 72.6%, 2002-2010: 87.1%, P < 0.0001). The frequency of ER-positive tumors also significantly increased in women over 50 years of age (1982-1991: 69.4%, 1992-2001: 73.3%, 2002-2010: 78.6%, P = 0.029). In ER-positive, HER2-negative breast cancer, tumor grade was negatively correlated with expression levels of ER and PgR. Prognosis for patients with ER-positive, HER2-negative disease significantly improved over time, due to advances in adjuvant therapies. Conclusion: It is necessary to establish risk factors, both genetic and environmental, capable of predicting the risk of ER-positive breast cancer and thus enable the efficient selection of candidates for hormone receptor-targeted chemoprevention.
引用
收藏
页码:1318 / 1325
页数:8
相关论文
共 30 条
  • [1] Allred DC, 1998, MODERN PATHOL, V11, P155
  • [2] Predicting risk of breast cancer in postmenopausal women by hormone receptor status
    Chlebowski, Rowan T.
    Anderson, Garnet L.
    Lane, Dorothy S.
    Aragaki, Aaron K.
    Rohan, Thomas
    Yasmeen, Shagufta
    Sarto, Gloria
    Rosenberg, Carol A.
    Hubbell, F. Allan
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (22): : 1695 - 1705
  • [3] Risk factors for breast cancer according to estrogen and progesterone receptor status
    Colditz, GA
    Rosner, BA
    Chen, WY
    Holmes, MD
    Hankinson, SE
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (03): : 218 - 228
  • [4] Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
    Dowsett, M
    Ebbs, SR
    Dixon, JM
    Skene, A
    Griffith, C
    Boeddinghaus, I
    Salter, J
    Detre, S
    Hills, M
    Ashley, S
    Francis, S
    Walsh, G
    Smith, IE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2477 - 2492
  • [5] Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
    Dowsett, Mitch
    Allred, Craig
    Knox, Jill
    Quinn, Emma
    Salter, Janine
    Wale, Chris
    Cuzick, Jack
    Houghton, Joan
    Williams, Norman
    Mallon, Elizabeth
    Bishop, Hugh
    Ellis, Ian
    Larsimont, Denis
    Sasano, Hironobu
    Carder, Pauline
    Cussac, Antonio Llombart
    Knox, Fiona
    Speirs, Valerie
    Forbes, John
    Buzdar, Aman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1059 - 1065
  • [6] Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
    Dowsett, Mitch
    Cuzick, Jack
    Wale, Christopher
    Forbes, John
    Mallon, Elizabeth A.
    Salter, Janine
    Quinn, Emma
    Dunbier, Anita
    Baum, Michael
    Buzdar, Aman
    Howell, Anthony
    Bugarini, Roberto
    Baehner, Frederick L.
    Shak, Steven
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1829 - 1834
  • [7] Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
    Dowsett, Mitch
    Cuzick, Jack
    Ingle, Jim
    Coates, Alan
    Forbes, John
    Bliss, Judith
    Buyse, Marc
    Baum, Michael
    Buzdar, Aman
    Colleoni, Marco
    Coombes, Charles
    Snowdon, Claire
    Gnant, Michael
    Jakesz, Raimund
    Kaufmann, Manfred
    Boccardo, Francesco
    Godwin, Jon
    Davies, Christina
    Peto, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 509 - 518
  • [8] Ellis MJ, 2003, CANCER RES, V63, P6523
  • [9] Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor Status
    Garcia-Closas, Montserrat
    Chanock, Stephen
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (24) : 8000 - 8009
  • [10] Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
    Goldhirsch, A.
    Ingle, J. N.
    Gelber, R. D.
    Coates, A. S.
    Thuerlimann, B.
    Senn, H. -J.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (08) : 1319 - 1329